# US 8,771,677 B2 · Colony-forming unit cell of human chorion and method to obtain and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,677 B2
- Document ID: US8771677B2
- Status: Granted
- Kind: B2
- Application number: 12/591,857
- Filed: 2009-12-03
- Published: 2010-07-01
- Granted: 2014-07-08
- Earliest claimed: 2008-12-29
- Applicants: Vladimir B Serikov; Frans A Kuypers
- Inventors: Vladimir B Serikov; Frans A Kuypers
- Web page: https://patentgrep.com/patent/US8771677B2

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type.

## Claims

### Claim 1

Isolated colony-forming unit cells derived from the chorion of human term placentas, wherein the isolated colony-forming unit cells are multipotent stem cells characterized by:
I) expression of protein ACBD6;
II) low telomerase activity and ability to be propagated over at least 70 doublings in vitro culture without substantial alteration of karyotype;
III) expression of a combination of at least one of the markers from each of:
iv) CD-90, SSEA-3, or TRA-1-60;
v) a Nanog cytosolic polypeptide;
vi) a neurofilament family cytosolic polypeptide;
vii) a Nestin cytosolic polypeptide; and
viii) one or more secreted polypeptides selected from a family of fibroblast growth factors, hepatocyte growth factors, keratinocyte growth factors, and angiopoietins; and
ix) nuclear peptide Oct-4;
IV) lack the ability for spontaneous differentiation into lineages of 3 germ layers under standard culture conditions, unless specifically stimulated and lack the ability for formation of teratomas in humans or immuno-compromised animals;
V) ability to differentiate into lineages of all 3 germ layers when the cells are exposed to lineage-specific differentiation conditions;
VI) ability to grow without adherence to plastic; and
VII) inability to form embryoid-like bodies.

### Claim 2 (depends on 1)

The isolated colony-forming unit cells of claim 1, wherein the cells are capable of repopulating organs of humans or immunodeficient animals without formation of teratomas.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising isolated colony-forming unit cells of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising isolated colony-forming unit cells of claim 1, an effective amount of any other cell population, and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A tissue-engineered construct, comprising isolated colony-forming unit cells of claim 1 and a biocompatible polymer scaffold.

### Claim 6 (depends on 1)

A method of enhancing regeneration of diseased tissue of organs, comprising administering to the diseased tissue the cells of claim 1 by local or systemic delivery of said cells.

### Claim 7 (depends on 6)

A method of claim 6 where the organ is heart.

### Claim 8 (depends on 6)

A method of claim 6 where the organ in spinal cord.

### Claim 9 (depends on 6)

A method of claim 6 where the organ is striated muscle.

### Claim 10 (depends on 6)

A method of claim 6 where the organ is peripheral nerve.